全文获取类型
收费全文 | 1458篇 |
免费 | 29篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 78篇 |
妇产科学 | 31篇 |
基础医学 | 156篇 |
口腔科学 | 48篇 |
临床医学 | 161篇 |
内科学 | 278篇 |
皮肤病学 | 52篇 |
神经病学 | 80篇 |
特种医学 | 24篇 |
外科学 | 169篇 |
综合类 | 87篇 |
预防医学 | 65篇 |
眼科学 | 37篇 |
药学 | 144篇 |
中国医学 | 23篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 6篇 |
2022年 | 7篇 |
2021年 | 47篇 |
2020年 | 20篇 |
2019年 | 147篇 |
2018年 | 101篇 |
2017年 | 70篇 |
2016年 | 21篇 |
2015年 | 18篇 |
2014年 | 68篇 |
2013年 | 51篇 |
2012年 | 57篇 |
2011年 | 61篇 |
2010年 | 47篇 |
2009年 | 53篇 |
2008年 | 45篇 |
2007年 | 40篇 |
2006年 | 47篇 |
2005年 | 35篇 |
2004年 | 24篇 |
2003年 | 19篇 |
2002年 | 26篇 |
2001年 | 26篇 |
2000年 | 12篇 |
1999年 | 15篇 |
1998年 | 7篇 |
1997年 | 14篇 |
1996年 | 11篇 |
1995年 | 7篇 |
1994年 | 10篇 |
1993年 | 3篇 |
1992年 | 11篇 |
1991年 | 6篇 |
1990年 | 5篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 7篇 |
1985年 | 45篇 |
1984年 | 63篇 |
1983年 | 37篇 |
1982年 | 51篇 |
1981年 | 51篇 |
1980年 | 28篇 |
1979年 | 29篇 |
1978年 | 17篇 |
1977年 | 16篇 |
1976年 | 9篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1972年 | 3篇 |
排序方式: 共有1500条查询结果,搜索用时 203 毫秒
1.
《Pancreatology》2022,22(7):880-886
BackgroundPremature intracellular trypsinogen activation has long been considered a key initiator of acute pancreatitis (AP). Cathepsin B (CTSB) activates trypsinogen, while cathepsin L (CTSL) inactivates trypsin(ogen), and both proteins play a role in the onset of AP.MethodsAP was induced by 7 hourly intraperitoneal injections of cerulein (50 μg/kg) in wild-type and pancreas-specific conditional Ctsb knockout (CtsbΔpan), Ctsl knockout (CtslΔpan), and Ctsb;Ctsl double-knockout (CtsbΔpan;CtslΔpan) mice. Pancreatic samples were collected and analyzed by histology, immunohistochemistry, real-time PCR, and immunoblots. Trypsin activity was measured in pancreatic homogenates. Peripheral blood was collected, and serum amylase activity was measured.ResultsDouble deletion of Ctsb and Cstl did not affect pancreatic development or mouse growth. After 7 times cerulein injections, double Ctsb and Ctsl deficiency in mouse pancreases increased trypsin activity to the same extent as that in Ctsl-deficient mice, while Ctsb deficiency decreased trypsin activity but did not affect the severity of AP. CtsbΔpan;CtslΔpan mice had comparable serum amylase activity and histopathological changes and displayed similar levels of proinflammatory cytokines, apoptosis, and autophagy activity compared with wild-type, CtsbΔpan, and CtslΔpan mice.ConclusionDouble deletion of Ctsb and Ctsl in the mouse pancreas altered intrapancreatic trypsin activity but did not affect disease severity and inflammatory response after cerulein-induced AP. 相似文献
2.
《Clinical colorectal cancer》2022,21(2):80-88
Lateral lymph nodes in low, locally advanced, rectal cancer have proven implications for local recurrence rates, which increase drastically in the presence of persistently enlarged lateral lymph nodes. These clinical implications warrant a thorough understanding of lateral nodal disease with awareness and knowledge from all three specialties involved – radiology, radiation oncology, and surgery – to ensure proper treatment. Relevant literature for each specialty, including all current guidelines and perspectives, were examined. Variations in definitions and treatment paradigms were evaluated. There is still no consensus for the standardized treatment of lateral nodal disease. Each discipline works according to their own available evidence, but relevant data are scarce. Current international guidelines and standard recommendations for the diagnostics and treatment of lateral lymph nodes are lacking. This results in differing perspectives and interpretations between the disciplines which can lead to challenging communication in an area where multidisciplinary collaboration is essential. This review addresses this by presenting the current evidence, perspectives and practices of each specialty and makes suggestions for each phase of the diagnostic and treatment process for patients with lateral nodal disease. By doing this, steps are taken toward achieving international consensus, and multidisciplinary collaboration. 相似文献
3.
4.
5.
6.
《Clinical Lymphoma, Myeloma & Leukemia》2019,19(5):275-284
BackgroundDaratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and newly diagnosed multiple myeloma. Preclinical daratumumab studies demonstrated cytotoxic activity and reduced tumor growth in B-cell non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle-cell lymphoma (MCL).Patients and MethodsThis was a phase 2, open-label, multicenter, 2-stage trial. Patients with relapsed/refractory DLBCL, FL, or MCL with ≥ 50% CD38 expression were eligible for stage 1. Daratumumab (16 mg/kg; 28-day cycles) was administered intravenously weekly for 2 cycles, every 2 weeks for 4 cycles, and every 4 weeks thereafter. Overall response rate was the primary end point. Pharmacokinetic and safety were also evaluated. Stage 2 was planned to further assess daratumumab in larger populations of NHL subtypes if futility criteria were not met. The study was registered with ClinicalTrials.gov (NCT02413489).ResultsThe trial screened 138 patients resulting in accrual of 15 patients with DLBCL, 16 with FL, and 5 with MCL. Median CD38 expression across treated patients was 70%. Overall response rate was 6.7%, 12.5%, and not evaluable in DLBCL, FL, and MCL cohorts, respectively. The most common grade 3/4 treatment-emergent adverse event was thrombocytopenia (11.1%), and 4 (11.1%) patients discontinued treatment because of treatment-emergent adverse events. Infusion-related reactions occurred in 72.2% of patients (3 patients with grade 3; no grade 4).ConclusionIn NHL, the safety and pharmacokinetics of daratumumab were consistent with myeloma studies. Screen-fail rates were high, prespecified futility thresholds were met in 2 cohorts, and the study was terminated. Studies in other hematologic malignancies and amyloidosis are ongoing. 相似文献
7.
8.
目的:探讨蓝莓花青素(BA)对人胃腺癌BGC-823细胞增殖、侵袭的影响及相关机制。方法:低、中、高剂量实验组与对照组人胃腺癌BGC-823细胞分别以25、50、100μg/mL BA与等量生理盐水处理,分别处理12 h、24 h、48 h。采用噻唑蓝(MTT)与流式细胞仪检测人胃腺癌BGC-823细胞增殖与凋亡;采用Transwell小室实验与免疫细胞化学法检测人胃腺癌BGC-823细胞侵袭与P53、半胱氨酸蛋白酶-3(Caspase-3)蛋白表达。结果:干预48 h时,对照组、低、中、高剂量实验组人胃腺癌BGC-823细胞P53与Caspase-3蛋白阳性细胞百分比分别为(11.12±1.01)%,(24.31±2.18)%,(47.56±2.91)%,(66.49±5.14)%与(15.04±1.23)%,(28.22±3.09)%,(69.36±5.42)%,(86.52±6.15)%。实验组胃腺癌BGC-823细胞增殖抑制率随BA浓度增大而逐渐升高;与对照组比较,低、中、高剂量实验组人胃腺癌BGC-823细胞凋亡率、P53与Caspase-3蛋白阳性细胞百分比均显著升高,侵袭率降低,呈浓度依赖性(均P0.05)。结论:BA可有效抑制胃腺癌BGC-823细胞增殖,诱导其凋亡,并降低侵袭能力,其机制可能与上调P53与Caspase-3蛋白表达有关。 相似文献
9.